相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G. Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2023)
Exercise-induced engagement of the IL-15/1L-15Rα axis promotes anti-tumor immunity in pancreatic cancer
Emma Kurz et al.
CANCER CELL (2022)
Non-Small Cell Lung Cancer, Version 3.2022
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
Herve Lena et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
S. M. Lee et al.
ANNALS OF ONCOLOGY (2022)
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade
Igor L. Gomes-Santos et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Enriqueta Felip et al.
EUROPEAN JOURNAL OF CANCER (2020)
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Francesco Facchinetti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Gary Middleton et al.
LANCET RESPIRATORY MEDICINE (2020)
Outcomes to first-line pembrolizumab in patients with PD-L1-high (>= 50%) non-small cell lung cancer and a poor performance status
Joao Alessi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
How the ageing microenvironment influences tumour progression
Mitchell Fane et al.
NATURE REVIEWS CANCER (2020)
Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status
Takayuki Fujio et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2019)
Development of immune checkpoint therapy for cancer
Jill M. Fritz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Methionine is a metabolic dependency of tumor-initiating cells
Zhenxun Wang et al.
NATURE MEDICINE (2019)
Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment
Sami Antoun et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Ziming Wang et al.
NATURE MEDICINE (2019)
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment
Hirotake Tsukamoto et al.
CANCER RESEARCH (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Anamorelin (ONO-7643) for the Treatment of Patients With Non-Small Cell Lung Cancer and Cachexia: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04)
Nobuyuki Katakami et al.
CANCER (2018)
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)
Eiji Iwama et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
Kenji Chamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction (vol 45, pg 374, 2016)
Nicole E. Scharping et al.
IMMUNITY (2016)
Muscling In on Cancer
Alejandro Lucia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
Mauro Zukin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study
Alessandro Morabito et al.
LUNG CANCER (2013)
Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2 West Japan Thoracic Oncology Group 0004
Hiroshi Saito et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Makoto Maemondo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Muscles, exercise and obesity: skeletal muscle as a secretory organ
Bente K. Pedersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
The effects of ghrelin on inflammation and the immune system
Dolgor Baatar et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer A Comprehensive Analysis of 26,957 Patients with NSCLC
Tomoya Kawaguchi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition
Jean-Paul Sculier et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599
Corey Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group
Paris A. Kosmidis et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)
RC Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
PJ Ross et al.
BRITISH JOURNAL OF CANCER (2004)
Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells
WG Li et al.
CIRCULATION (2004)
分享论文
